Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 06, 2017 07:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Announces EnteraGam® Poster Presentation at the ISPOR 20th Annual European Congress

TEL-AVIV, Israel and RALEIGH, N.C., Nov. 06, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical...
November 01, 2017 07:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma and IntelGenx Submit New Drug Application to FDA for RIZAPORT® for Migraines

RIZAPORT® is a proprietary oral thin-film formulation of rizatriptan for the treatment of acute migrainesA Prescription Drug User Fee Act (PDUFA) date is expected to be set by the FDA for the first...
October 26, 2017 07:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma to Present at the BIO-Europe 2017 Conference

TEL-AVIV, Israel and RALEIGH, N.C., Oct. 26, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical...
October 23, 2017 07:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Receives Notice of Allowance for a New U.S. Patent Covering RHB-104

The new patent, covering RHB-104 for relapsing-remitting multiple sclerosis (MS), is expected to be valid until 2032, once grantedEnrollment in the Phase III study with RHB-104 for Crohn’s disease to...
October 20, 2017 07:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Receives FDA Orphan Drug Designation for MESUPRON for Pancreatic Cancer

RedHill to benefit from various incentives to develop MESUPRON (upamostat) for the adjuvant treatment of pancreatic cancer, including a seven-year marketing exclusivity period for the indication, if...
October 19, 2017 08:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Announces Poster Presentation at the 2017 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference

TEL-AVIV, Israel and RALEIGH, N.C., Oct. 19, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical...
October 10, 2017 06:10 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma to Present at the BioNetwork 2017 Partnering Summit

TEL-AVIV, Israel and RALEIGH, N.C., Oct. 10, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical...
October 03, 2017 07:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Announces Positive Top-Line Results from Phase II Study of BEKINDA® in Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

BEKINDA®i 12 mg Phase II study successfully met its primary endpoint, improving primary efficacy outcome of stool consistency by an absolute difference of 19.4% vs. placebo and comparing favorably...
October 02, 2017 07:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Accelerates RHB-104 Phase III Study in Crohn’s Disease with Top-Line Results Expected Mid-2018

RedHill has curtailed the target sample size in the ongoing first Phase III study with RHB-104 for Crohn’s disease (MAP US) from 410 to approximately 325 subjects, of which 322 have been enrolled to...
September 28, 2017 07:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma to Announce Top-Line Results from BEKINDA® 12 mg Phase II Study for IBS-D on October 3rd, 2017

TEL-AVIV, Israel and RALEIGH, N.C., Sept. 28, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical...